About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

UNKNOWNPhase 3

Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy

Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study

NCT00300729•University Hospital, Linkoeping

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Non-Small Cell Lung Cancer

Interventions

Celecoxib

Placebo

Locations

13

Sweden

Locations (13)

Department of Pulmonary Medicine and Allergology, Sahlgrenska University Hospital

Gothenburg, Sweden

Section of Pulmonary Medicine, Ryhov County Hospital

Jönköping, Sweden

Section of Pulmonary Medicine and Allergology, County Hospital of Kalmar

Kalmar, Sweden

Department of Pulmonary Medicine, University Hospital

Linköping, Sweden

Department of Pulmonary Medicine and Allergy, Lund University Hospital

Lund, Sweden

Section of Pulmonary Medicine, Malmö University Hospital

Malmo, Sweden

Key Dates

Start Date

May 1, 2006

Primary Completion Date

May 1, 2010

Completion Date

September 1, 2010

Last Updated

June 30, 2009

Related Studies

RECRUITINGPhase 3

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

NCT06305754

Non-small Cell Lung Cancer (NSCLC)

RECRUITINGPhase 3

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248

Non-small Cell Lung Cancer

RECRUITINGPhase 2/3

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

NCT07100080

Non-Small Cell Lung Cancer

RECRUITINGPhase 3

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT07195695

Non-small Cell Lung Cancer

RECRUITINGPhase 3

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533

Non-Small Cell Lung Cancer

RECRUITINGPhase 2

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

NCT06731413

Non-Small Cell Lung CancerNSCLC+2 more

View all related studies

Sponsors

Lead Sponsor

University Hospital, Linkoeping

Collaborators

Swedish Lung Cancer Study Group
Pfizer

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 30, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions